Patent Issued for Topical application of CRISPR-modified bacteria to treat acne vulgaris (USPTO 11839632).

Seed Health Inc. has been granted a patent for using CRISPR-modified bacteria to treat acne vulgaris. The patent explains the importance of the skin microbiome and how certain bacteria can benefit skin health. The method involves applying a bacterial formulation to the skin to alter the microbiome and address specific concerns or diseases. The patent also suggests using prebiotics and extracts from helminths to enhance the effectiveness of the bacteria. The goal is to reduce the likelihood of skin conditions, such as acne vulgaris, and potentially prevent allergies, autoimmune diseases, and chronic inflammation by establishing immune tolerance to commensal microbes on the skin. The patent also mentions the use of immune checkpoint inhibitors and probiotic strains in combination with the bacterial formulation. [Extracted from the article]